Pulmonx (DE:4NI)
FRANKFURT:4NI
4NI Stock Chart & Stats
€1.58
-€0.05(-0.78%)
At close: 4:00 PM EST
€1.58
-€0.05(-0.78%)
Day’s Range― - ―
52-Week Range€0.99 - €3.18
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€55.28M
Enterprise Value€64.41M
Total Cash (Recent Filing)€61.57M
Total Debt (Recent Filing)€56.29M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 05, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding42,237,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.01Price Target Upside90.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.98
Revenue Forecast (FY)€78.04M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid-70s gross margins reflect strong unit economics for single-use valves and consumables. Durable margin profile supports reinvestment in commercialization and R&D as volumes scale, providing a structural cushion against operating losses and enabling a clearer path to profitability if procedure growth resumes.
Recurring, Procedure-driven Revenue ModelRevenue tied to per-procedure disposable valves creates recurring, predictable demand as more centers and physicians adopt the therapy. Continued expansion of treating centers and stabilized salesforce hiring increase throughput potential and long-term revenue visibility as centers ramp clinical volumes over multiple quarters.
Pipeline Expands Addressable MarketA successful AeriSeal pivotal would materially enlarge the treatable patient base and diversify product revenue beyond Zephyr. This represents a structural growth lever: new indications can drive sustained procedure volume growth and higher lifetime customer value, improving long-term revenue potential if regulatory and enrollment milestones are met.
Bears Say
Revenue Contraction And Demand HeadwindsYear-over-year revenue decline signals near-term loss of commercial momentum and weakens operating leverage. Persistent top-line softness makes it harder to cover fixed costs and extend profitability timelines, increasing execution risk as management must reaccelerate adoption amid competitive and reimbursement pressures.
Rising Leverage And Weakened EquityDebt-to-equity above 1x and shrinking equity reduce financial flexibility and increase default risk during downturns. Higher secured leverage can restrict strategic options, raise interest expense vulnerability, and elevate the chance of dilution or covenant-driven restructuring if growth and cash generation lag expectations.
Negative Cash Flow And Financing DependenceConsistent negative operating and free cash flow forces reliance on external financing and the recently closed term loan; this structurally increases refinancing and covenant risk. Ongoing cash burn narrows runway and raises the probability of additional financing or dilution if procedure growth and cost reductions do not produce sustained positive cash generation.
Pulmonx News
4NI FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was €0.99 and its highest was €3.18 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is €55.28M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Aug 05, 2026 which is in 60 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Apr 29, 2026. The company reported -€0.283 earnings per share for the quarter, missing the consensus estimate of -€0.281 by -€0.003.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.24.
How many shares outstanding does Pulmonx have?
Pulmonx has 42,237,200 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -€0.283 in its last earnings report, missing expectations of -€0.281. Following the earnings report the stock price went down -0.962%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in DE:4NI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.01 (90.75% Upside)
€3.01 (90.75% Upside)
Insider Transactions
Sold Shares
Worth €245.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.02%
12-Months-Change
Fundamentals
Return on Equity
-82.79%
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
4NI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixes clear near-term challenges (Q1 revenue declines, China registration-driven international disruption, ongoing net losses) with several meaningful positive developments: improved gross margin, cost reductions lowering operating expense trajectory, strengthened liquidity via a $60M credit facility, addition of U.S. treating centers and filled sales roles, and progressing pivotal clinical enrollment that could expand TAM by ~20%. Management reiterated full-year guidance of $90M–$92M and expects sequential improvement with a return to growth in H2 2026. The narrative is execution- and timing-dependent but supported by concrete operational and financial actions that materially reduce downside risk.View all DE:4NI earnings summaries4NI Stock 12 Month Forecast
Average Price Target
€3.01
▲(90.75% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Options Prices
Currently, No data available
---